USA flag logo/image

An Official Website of the United States Government

Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AI100467
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
GENVEC, INC.
910 Clopper Road  Suite 220N GAITHERSBURG, MD 20878
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development
Agency: HHS
Contract: 1R43AI100467-01
Award Amount: $600,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The development of an effective malaria vaccine is a high global health priority. Malaria is the most burdensome parasitic disease of man, exacting an estimated toll of 863,000 deaths and 243 million clinical cases peryear. There is an urgent need for a safe and effective malaria vaccine. An abundance of data in rodents, non-human primates and humans indicate the existence of protective antigens in whole organism malaria vaccines that induce T cells which target the pre-erythrocytic stages of the malaria parasite. However, the specific antigen targets of this protective immunity are not known. Our overall goal is to identify novel, highly protective, pre-erythrocytic antigens for malaria vaccine development. Our hypothesis is that the pre- erythrocytic P. yoelii antigens that are the targets of protective cell responses induced by immunization with highly protective regimens of live sporozoites under chloroquine prophylaxis will induce robust and protective immune responses in mice when delivered by adenovectors; and that the corresponding P. falciparum orthologues will be good candidate antigens for malaria vaccine development. We propose a rational and systematic approach to identify these novel highly protective, pre-erythrocytic antigens. We have already developed an array of adenovectors that express 300 of the most highly expressed pre-erythrocytic P. yoelii antigens, and will screen this array to identify antigens that recall robust T cell responses from mice immunized with live sporozoites under chloroquine prophylaxis (Specific Aim 1). Adenovectors from the array that recall the strongest T cell responses will be purified and evaluated for their ability to induce protective immune responses in mice (Specific Aim2). Transitioning to preclinical development, we will build hexon-modified Ad5 vectors expressing the P. falciparum orthologues of the three most protective antigens and evaluate their capacity to induce T cell and antibody responses in mice (Specific Aim3). Success in achievement of these aims will advance three new pre-erythrocytic antigens to malaria vaccine development. PUBLIC HEALTH RELEVANCE: There is an urgent need for a safe and effective malaria vaccine and the development of such a vaccine is a global health priority. Pre-erythrocytic antigens can induce protective responses against malaria, however, very few of these antigens have been identified and these are not sufficient to confer high levels of protection. The goal of this project is to identify novel, highly protective, pre-erythrocytic antigens for malaria vaccine development.

Principal Investigator:

Joseph T. Bruder
240-632-5543
jbruder@genvec.com

Business Contact:

Leslie W. Bushby
240-632-5572
lwest-bushby@genvec.com
Small Business Information at Submission:

GENVEC, INC.
910 Clopper Road  Suite 220N GAITHERSBURG, MD 20878

EIN/Tax ID: 123270569
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No